OPRK1 promoter hypermethylation increases the risk of Alzheimer's disease

Neuroscience Letters

Volumn 606, Issue , 2015, Pages 24-29

  Ji, Huihui ^a   Wang, Yunliang ^b   Liu, Guili ^a   Xu, Xuting ^a   Dai, Dongjun ^a   Chen, Zhongming ^c   Zhou, Dongsheng ^c   Zhou, Xiaohui ^d   Han, Liyuan ^a   Li, Ying ^e   Zhuo, Renjie ^a   Hong, Qingxiao ^a   Jiang, Liting ^a   Zhang, Xiaonan ^a   Liu, Yu ^a   Xu, Lei ^a   Chang, Lan ^a   Li, Jinfeng ^b   An, Pengyuan ^a   Duan, Shiwei ^a   Wang, Qinwen ^a   more..

^a NINGBO UNIVERSITY   (China)

^b The 148 Central Hospital of PLA   (China)

^c Ningbo Kangning Hospital   (China)

^d XINJIANG MEDICAL UNIVERSITY   (China)

^e NINGBO FIRST HOSPITAL   (China)

Author keywords

Alzheimer disease; DNA methylation; Expression; OPRK1; Promoter

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION; GENETIC RISK; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MALE; OPRK 1 GENE; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; REPORTER GENE; RISK ASSESSMENT; CASE CONTROL STUDY; CPG ISLAND; GENETICS; HEK293 CELL LINE; METABOLISM; VERY ELDERLY;

KAPPA OPIATE RECEPTOR; OPRK1 PROTEIN, HUMAN;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; FEMALE; HEK293 CELLS; HUMANS; MALE; PROMOTER REGIONS, GENETIC; RECEPTORS, OPIOID, KAPPA;

EID: 84940555473     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.08.027     Document Type: Article

References (28)

1. Fletcher L.C., Burke K.E., Caine P.L., Rinne N.L., Braniff C.A., Davis H.R., Miles K.A., Packer C. Diagnosing Alzheimer's disease: are we any nearer to useful biomarker-based, non-invasive tests?. GMS Health Technol. Assess. 2013, 9. Doc01.
2. Catricala S., Torti M., Ricevuti G. Alzheimer disease and platelets: how's that relevant. Immun. Ageing 2012, 9:20.
3. Chan K.Y., Wang W., Wu J.J., Liu L., Theodoratou E., Car J., Middleton L., Russ T.C., Deary I.J., Campbell H., Wang W., Rudan I. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet 2013, 381:2016-2023. Global Health Epidemiology Reference Group.
4. Kubota T. Epigenome: what we learned from Rett syndrome, a neurological disease caused by mutation of a methyl-CpG binding protein. Rinsho Shinkeigaku = Clin. Neurol. 2013, 53:1339-1341.
5. Xu X., Wang Y., Wang L., Liao Q., Chang L., Xu L., Huang Y., Ye H., Xu L., Chen C., Shen X., Zhang F., Ye M., Wang Q., Duan S. Meta-analyses of 8 polymorphisms associated with the risk of the Alzheimer's disease. PloS One 2013, 8:e73129.
6. Barfield R.T., Almli L.M., Kilaru V., Smith A.K., Mercer K.B., Duncan R., Klengel T., Mehta D., Binder E.B., Epstein M.P., Ressler K.J., Conneely K.N. Accounting for population stratification in DNA methylation studies. Genet. Epidemiol. 2014, 38:231-241.
7. Van den Hove D.L., Kompotis K., Lardenoije R., Kenis G., Mill J., Steinbusch H.W., Lesch K.P., Fitzsimons C.P., De Strooper B., Rutten B.P. Epigenetically regulated microRNAs in Alzheimer's disease. Neurobiol. Aging. 2014, 35:731-745.
8. Deng Y., Yu G. The effect of DNA methylation on beta-amyloid accumulation in Alzheimer's disease. Yi chuan = Hereditas /Zhongguo Yi Chuan Xue Hui Bian Ji 2014, 36:295-300.
9. Peckys D., Landwehrmeyer G.B. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience 1999, 88:1093-1135.
10. Menard C., Herzog H., Schwarzer C., Quirion R. Possible role of dynorphins in Alzheimer's disease and age-related cognitive deficits. Neurodegener. Dis. 2014, 13:82-85.
11. Silva P.N., Furuya T.K., Braga I.L., Rasmussen L.T., Labio R.W., Bertolucci P.H., Chen E.S., Turecki G., Mechawar N., Payao S.L., Mill J., Smith M.C. Analysis of HSPA8 and HSPA9 mRNA expression and promoter methylation in the brain and blood of Alzheimer's disease patients. J. Alzheimer's Dis. 2014, 38:165-170.
12. Sunderland T., Berrettini W.H., Molchan S.E., Lawlor B.A., Martinez R.A., Vitiello B., Tariot P.N., Cohen R.M. Reduced cerebrospinal fluid dynorphin A1-8 in Alzheimer's disease. Biol. Psychiatry 1991, 30:81-87.
13. Chang L., Wang Y., Ji H., Dai D., Xu X., Jiang D., Hong Q., Ye H., Zhang X., Zhou X., Liu Y., Li J., Chen Z., Li Y., Zhou D., Zhuo R., Zhang Y., Yin H., Mao C., Duan S., Wang Q. Elevation of peripheral BDNF promoter methylation links to the risk of Alzheimer's disease. PLoS One 2014, 9:e110773.
14. Sanchez-Mut J.V., Aso E., Heyn H., Matsuda T., Bock C., Ferrer I., Esteller M. Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease. Hippocampus 2014, 24:363-368.
15. Furuya T.K., da Silva P.N., Payao S.L., Rasmussen L.T., de Labio R.W., Bertolucci P.H., Braga I.L., Chen E.S., Turecki G., Mechawar N., Mill J., de Arruda Cardoso Smith M. SORL1 and SIRT1 mRNA expression and promoter methylation levels in aging and Alzheimer's Disease. Neurochem. Int. 2012, 61:973-975.
16. Prezelj M. Enzymic determination of total bilirubin in serum with the BA-1000. Clin. Chem. 1988, 34:176-177.
17. Friedman S.M. Measurement of sodium and potassium by glass electrodes. Methods Biochem. Anal. 1962, 10:71-106.
18. Tregoat V., Montagne P., Cuilliere M.L., Bene M.C., Faure G.C. Sequential C3 and C4 levels in human milk in relation to prematurity and parity. Clin. Chem. Lab. Med. 2000, 38:609-613.
19. Jiang D., Zheng D., Wang L., Huang Y., Liu H., Xu L., Liao Q., Liu P., Shi X., Wang Z., Sun L., Zhou Q., Li N., Xu L., Le Y., Ye M., Shao G., Duan S. Elevated PLA2G7 gene promoter methylation as a gender-specific marker of aging increases the risk of coronary heart disease in females. PLoS One 2013, 8:e59752.
20. Mathieu-Kia A.M., Fan L.Q., Kreek M.J., Simon E.J., Hiller J.M. Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res. 2001, 893:121-134.
21. Wang F., Fischhaber P.L., Guo C., Tang T.S. Epigenetic modifications as novel therapeutic targets for Huntington's disease. Epigenomics 2014, 6:287-297.
22. Fratiglioni L., Viitanen M., von S., trauss E., Tontodonati V., Herlitz A., Winblad B. Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology 1997, 48:132-138.
23. Lardenoije R., Iatrou A., Kenis G., Kompotis K., Steinbusch H.W., Mastroeni D., Coleman P., Lemere C.A., Hof P.R., van den Hove D.L., Rutten B.P. The epigenetics of aging and neurodegeneration. Progress Neurob. 2015, 131:21-64.
24. Penaloza C.G., Estevez B., Han D.M., Norouzi M., Lockshin R.A., Zakeri Z. Sex-dependent regulation of cytochrome P450 family members Cyp1a1, Cyp2e1, and Cyp7b1 by methylation of DNA. FASEB J. 2014, 28:966-977.
25. Piferrer F. Epigenetics of sex determination and gonadogenesis. Dev. Dyn.: Off. Publ. Am. Assoc. Anatomists 2013, 242:360-370.
26. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 1987, 235:1043-1046.
27. Kim T.S., Pae C.U., Yoon S.J., Jang W.Y., Lee N.J., Kim J.J., Lee S.J., Lee C., Paik I.H., Lee C.U. Decreased plasma antioxidants in patients with Alzheimer's disease. Int. J. Geriatric Psychiatry 2006, 21:344-348.
28. Butterworth R.F. Hepatic encephalopathy in alcoholic cirrhosis. Handbook of Clinical Neurology 2014, vol 125:589-602.